Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Sponsor
Bayer
Study ID
NCT02585401
Status
Completed

Conditions

  • Age-related Macular Degeneration (AMD)
  • Central Retinal Vein Occlusion (CRVO)
  • Diabetic Macular Edema (DME)

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

  • Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) — DRUG
    The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.

Study Details

The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.

Key Dates

Start date
Feb 18, 2016
Status verified
Mar 2017
Primary completion
Mar 31, 2016
Completion
May 19, 2016

Study Design

Enrollment
99 participants (actual)

Arms

  • Arm: Eylea product and application information / Cohort 1
    Physicians prescribing aflibercept in Canada will be selected to reflect the distribution of retinal specialists and ophthalmologists who prescribe aflibercept.

Primary Outcome Measure

Knowledge and understanding of key information contained in the aflibercept educational materials: the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph [ Time Frame: Up to 8 weeks after the start of data collection ]

Related Studies